Study Identifier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HIV Cure Program Releases Initial Clinical Trial Data July 15, 2021 23:51 ET | Source: American Gene Technologies American Gene Technologies Rockville, Maryland, UNITED STATES ROCKVILLE, Md., July 15, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene...

/PRNewswire/ -- American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical...

LGBT+ Investment Firm Gaingels Joins American Gene Technologies' Mission to Cure HIV, and Other Serious Human Diseases News provided by Share this article , an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease. This investment places Gaingels alongside private investors who ...

(1) BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first patient cohort (n=3) in a Phase I dose escalation study, evaluating the safety and efficacy of Tessa's TT11X - Allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy. The Phase 1 study being conducted at Baylor College of Medicine aims to enroll up to 18 patients with CD30+ lymphoma a...